SCHEMBL12149598

SCHEMBL12149598

CCc1ncccc1-c1ccc(C(=O)O)c(OCc2cccc3ccccc23)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.60
▸ MCL1 Q07820 4/20 0.53
▸ PARP15 Q460N3 1/20 0.45
▸ PARP10 Q53GL7 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ EDNRA P25101 1/20 0.41
▸ ACMSD Q8TDX5 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ DHODH Q02127 1/20 0.40
▸ SYK P43405 1/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ AKR1B1 P15121 1/20 0.40
▸ SGMS2 Q8NHU3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13389729 0.86 FDPS (0.60) FDPSMCL1PARP15PARP10MEN1
SCHEMBL1375302 0.83 FDPS (0.66) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149663 0.83 FDPS (0.65) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149637 0.81 FDPS (0.63) FDPSMCL1PARP15PARP10MEN1
SCHEMBL1378315 0.81 FDPS (0.78) FDPSMCL1PARP15PARP10MEN1
SCHEMBL27861648 0.80 FDPS (0.62) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149699 0.79 FDPS (0.74) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149693 0.78 FDPS (0.70) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149617 0.78 FDPS (0.67) FDPSMCL1PARP15PARP10MEN1
SCHEMBL12149587 0.78 FDPS (0.70) FDPSMCL1PARP15PARP10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY FDPS 1/4885MCL1 3077/4885PARP15 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback